Bernd Muehlenweg

Non Executive Director @Sernova

Hamburg, DE
MOBILE NUMBERS
+91 *********19

Signup · Get unlimited contacts

WORK HISTORY

Apr 2024 — Present

Non Executive Director @Sernova

View department →

Sernova (TSX: SVA)(OTCQB: SEOVF) is a clinical-stage biotechnology company that is advancing a novel cell therapy platform for the treatment of chronic diseases. The lead program is evaluating Sernova\'s Cell Pouch System™ as a potential ‘functional cure’ for insulin-dependent diabetes. In addition, Sernova has a pipeline that includes preclinical programs in hemophilia A and hypothyroidism.

EDUCATION

1997 — 2000

Technical University of Munich

Ph.D., Oncology, Biochemistry

2006 — 2006

St. Galler Business School

Management

1991 — 1996

Bielefeld University

Dipl. Chem., Chemistry, Biochemistry

1995 — 1995

Dublin City University

Dipl. Chem., Biophysical Chemistry

SKILLS

Board LevelValuationLife SciencesLicensingCommercializationDrug DevelopmentBiopharmaceuticalsDue DiligenceVenture CapitalOncologyMergers & AcquisitionsNanotechnologyLifesciencesBusiness PlanningBusiness DevelopmentBiotechnologyCorporate DevelopmentMergersMarket Analysis

ABOUT BERND MUEHLENWEG

Experienced biopharma executive with a strong track record in global business development, corporate strategy, and alliance management.Passionate about translating cutting-edge science into impactful therapies, I bring over two decades of leadership in building partnerships, securing strategic deals, and advancing novel platforms and assets from discovery to clinical stage. I thrive in fast-paced environments where innovation meets execution — always with a focus on patient-centric outcomes.

This profile is compiled from publicly available professional sources. Unifers is not affiliated with or endorsed by LinkedIn. Request removal of this profile.